Apollo Therapeutics Group Ltd.

Apollo Therapeutics is about to find out if its novel portfolio-building approach to biotech can pay off, starting with a Phase II readout from its IL-18 candidate in atopic dermatitis. The UK-headqua

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

Apollo Therapeutics is to work closely with University of Oxford to help its academic scientists bring more novel potential first-in-class therapeutics to patients. That means Apollo is now a partner

Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the la